1.26
+2.44%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Crossject
Its shares trade on Euronext Paris under the ticker ALCJ.PA. In the fiscal year to 31 December 2024, it reported revenue of €4.1m and a net loss of €12.8m. At that date it held total assets of €31.6m and shareholders' equity of −€2.7m.
Crossject SA manufactures and markets needle-free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject’s first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The firm has industrial partnerships with Hirtenberger and Recipharm.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Employees
- 88
- Website
- crossject.com ↗
Leadership
Pay as last reported
- Mr. Philippe MonnotChairman of the Supervisory Board
- Mr. Patrick AlexandreChairman of the Management Board, Co-Founder, since 2012
- Mr. Eric NemethIndependent Vice Chairman of the Supervisory Board
- Dr. Dan ChicheChief Medical Officer
- Mr. Henri De ParsevalMember of the Management Board
- Mr. Jean-Francois LoumeauMember of the Supervisory Board
- Dr. Yannick PletanMember of the Supervisory Board
- Dr. Daniel TeperMember of the Supervisory Board
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Crossject SA has several strengths that contribute to its competitive advantage in the market. Firstly, the company possesses a unique and innovative drug delivery technology known as Zeneo®, which enables the painless and efficient administration of drugs. This technology offers significant advantages over traditional injection methods, making it a valuable asset for Crossject SA.
- Additionally, Crossject SA has a strong intellectual property portfolio, including various patents and trademarks, which provide legal protection and exclusivity for their innovative drug delivery systems. This further strengthens the company's position in the market and acts as a barrier to entry for potential competitors.
- Furthermore, the company has formed strategic partnerships with established pharmaceutical companies. These partnerships not only bring financial benefits to Crossject SA but also provide access to a wide range of resources, including expertise, distribution channels, and market opportunities.
Weaknesses
- Despite its strengths, Crossject SA also has some weaknesses that need to be addressed. One notable weakness is the relatively limited market presence and brand recognition compared to well-established competitors. This can pose challenges in terms of market penetration and attracting a broad customer base.
- Moreover, the production and commercial scale-up of their drug delivery systems may present a weakness. Maintaining a stable and cost-effective production process while meeting the increasing demand can be challenging, especially for a relatively small company like Crossject SA.
Opportunities
- The market for innovative drug delivery systems is growing rapidly, driven by the rising demand for easier and less invasive administration methods. Crossject SA can capitalize on this opportunity by leveraging its unique technology and expanding its product portfolio to cater to different therapeutic areas and market segments.
- Furthermore, the increasing focus on self-medication and home healthcare presents an opportunity for Crossject SA. Their painless and user-friendly drug delivery systems align well with these trends and can attract a significant customer base seeking convenient and reliable self-administration options.
Threats
- Crossject SA faces threats from both existing competitors and potential new entrants in the market. Established pharmaceutical companies may try to imitate or develop similar drug delivery technologies, challenging Crossject SA's competitive advantage. Additionally, evolving regulations and reimbursement policies in the healthcare industry can impact the adoption and commercial success of the company's products.
- Moreover, unexpected events such as regulatory setbacks, manufacturing disruptions, or economic downturns can significantly impact the company's operations and financial performance. Crossject SA needs to mitigate these threats through effective risk management strategies and continuous innovation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.